Ascendis Pharma A/S (ASND)
237.57
-0.02
(-0.01%)
USD |
NASDAQ |
Sep 22, 16:00
239.44
+1.87
(+0.79%)
Pre-Market: 08:49
Ascendis Pharma EPS Diluted (Annual) : -4.246 for Dec. 31, 2025
EPS Diluted (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -4.246 |
| December 31, 2024 | -7.064 |
| December 31, 2023 | -9.247 |
| December 31, 2022 | -10.93 |
| December 31, 2021 | -8.278 |
| December 31, 2020 | -9.436 |
| December 31, 2019 | -5.247 |
| Date | Value |
|---|---|
| December 31, 2018 | -3.736 |
| December 31, 2017 | -4.151 |
| December 31, 2016 | -2.854 |
| December 31, 2015 | -1.541 |
| December 31, 2014 | -0.5438 |
| December 31, 2013 | 0.2257 |
| December 31, 2012 | 0.0642 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Annual) Benchmarks
| BioMarin Pharmaceutical, Inc. | 1.805 |
| Novo Nordisk A/S | 3.483 |
| Evaxion AS | -1.206 |
| Genmab A/S | 1.541 |
| Zealand Pharma A/S | 13.64 |